;PMID: 12141399
;source_file_1866.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..39] = [t:0..39]
;1)sentence:[e:45..113] = [t:45..113]
;2)section:[e:117..145] = [t:117..145]
;3)section:[e:149..263] = [t:149..263]
;4)sentence:[e:267..454] = [t:267..454]
;5)sentence:[e:455..627] = [t:455..627]
;6)sentence:[e:628..730] = [t:628..730]
;7)sentence:[e:731..809] = [t:731..809]
;8)sentence:[e:810..944] = [t:810..944]
;9)sentence:[e:945..1107] = [t:945..1107]
;10)sentence:[e:1108..1271] = [t:1108..1271]
;11)sentence:[e:1272..1455] = [t:1272..1455]
;12)sentence:[e:1456..1563] = [t:1456..1563]
;13)sentence:[e:1564..1669] = [t:1564..1669]
;14)section:[e:1673..1718] = [t:1673..1718]

;section 0 Span:0..39
;Hum Exp Toxicol. 2002 May;21(5):273-80.
(SEC
  (FRAG (NNP:[0..3] Hum) (NNP:[4..7] Exp) (NNP:[8..15] Toxicol) (.:[15..16] .)
        ('':[17..21] 2002) (NNP:[22..25] May) (CD:[25..28] ;21)
        (-LRB-:[28..29] -LRB-) (CD:[29..30] 5) (-RRB-:[30..31] -RRB-)
        (CD:[31..35] :273) (::[35..36] -) (CD:[36..38] 80) (.:[38..39] .)))

;sentence 1 Span:45..113
;Methylphenidate inhibits cytochrome P450 in the Swiss Webster mouse.
;[45..60]:substance:"Methylphenidate"
;[70..85]:cyp450:"cytochrome P450"
(SENT
  (S-HLN
    (NP-SBJ (NN:[45..60] Methylphenidate))
    (VP (VBZ:[61..69] inhibits)
      (NP (NN:[70..80] cytochrome) (NN:[81..85] P450))
      (PP-LOC (IN:[86..88] in)
        (NP (DT:[89..92] the) (JJ:[93..98] Swiss) (NNP:[99..106] Webster)
            (NN:[107..112] mouse))))
    (.:[112..113] .)))

;section 2 Span:117..145
;Le Nedelec MJ, Rosengren RJ.
(SEC
  (FRAG (NNP:[117..119] Le) (NNP:[120..127] Nedelec) (NNP:[128..130] MJ)
        (,:[130..131] ,) (NNP:[132..141] Rosengren) (NNP:[142..145] RJ.)))

;section 3 Span:149..263
;Department of Pharmacology and Toxicology, School of Medical Sciences, 
;University of Otago, Dunedin, New Zealand.
(SEC
  (FRAG (NNP:[149..159] Department) (IN:[160..162] of)
        (NNP:[163..175] Pharmacology) (CC:[176..179] and)
        (NNP:[180..190] Toxicology) (,:[190..191] ,) (NNP:[192..198] School)
        (IN:[199..201] of) (NNP:[202..209] Medical) (NNP:[210..218] Sciences)
        (,:[218..219] ,) (NNP:[221..231] University) (IN:[232..234] of)
        (NNP:[235..240] Otago) (,:[240..241] ,) (NNP:[242..249] Dunedin)
        (,:[249..250] ,) (NNP:[251..254] New) (NNP:[255..262] Zealand)
        (.:[262..263] .)))

;sentence 4 Span:267..454
;Drug interactions have previously been reported following the
;co-administration  of methylphenidate (MPH) and drugs metabolized by the
;cytochrome P450 (CYP450)  system such as imipramine.
;[267..271]:substance:"Drug"
;[351..366]:substance:"methylphenidate"
;[368..371]:substance:"MPH"
;[377..382]:substance:"drugs"
;[402..417]:cyp450:"cytochrome P450"
;[419..425]:cyp450:"CYP450"
;[443..453]:substance:"imipramine"
(SENT
  (S
    (NP-SBJ-1 (NN:[267..271] Drug) (NNS:[272..284] interactions))
    (VP (VBP:[285..289] have)
      (ADVP-TMP (RB:[290..300] previously))
      (VP (VBN:[301..305] been)
        (VP (VBN:[306..314] reported)
          (NP-1 (-NONE-:[314..314] *))
          (S-ADV
            (NP-SBJ (-NONE-:[314..314] *))
            (VP (VBG:[315..324] following)
              (NP
                (NP (DT:[325..328] the) (AFX:[329..331] co) (HYPH:[331..332] -)
                    (NN:[332..346] administration))
                (PP (IN:[348..350] of)
                  (NP
                    (NP
                      (NP (NN:[351..366] methylphenidate))
                      (NP (-LRB-:[367..368] -LRB-) (NN:[368..371] MPH)
                          (-RRB-:[371..372] -RRB-)))
                    (CC:[373..376] and)
                    (NP
                      (NP
                        (NP (NNS:[377..382] drugs))
                        (VP (VBN:[383..394] metabolized)
                          (NP (-NONE-:[394..394] *))
                          (PP (IN:[395..397] by)
                            (NP-LGS (DT:[398..401] the)
                              (NML
                                (NML (NN:[402..412] cytochrome)
                                     (NN:[413..417] P450))
                                (NML (-LRB-:[418..419] -LRB-)
                                     (NN:[419..425] CYP450)
                                     (-RRB-:[425..426] -RRB-)))
                              (NN:[428..434] system)))))
                      (PP (JJ:[435..439] such) (IN:[440..442] as)
                        (NP (NN:[443..453] imipramine))))))))))))
    (.:[453..454] .)))

;sentence 5 Span:455..627
;Therefore, this study used the Swiss Webster mouse to  determine the effect
;of MPH on CYP450 isozymes likely to be important in the  interaction between
;MPH and imipramine.
;[534..537]:substance:"MPH"
;[541..556]:cyp450:"CYP450 isozymes"
;[608..611]:substance:"MPH"
;[616..626]:substance:"imipramine"
(SENT
  (S
    (ADVP (RB:[455..464] Therefore))
    (,:[464..465] ,)
    (NP-SBJ (DT:[466..470] this) (NN:[471..476] study))
    (VP (VBD:[477..481] used)
      (NP (DT:[482..485] the) (JJ:[486..491] Swiss) (NNP:[492..499] Webster)
          (NN:[500..505] mouse))
      (S-PRP
        (NP-SBJ (-NONE-:[505..505] *))
        (VP (TO:[506..508] to)
          (VP (VB:[510..519] determine)
            (NP
              (NP (DT:[520..523] the) (NN:[524..530] effect))
              (PP (IN:[531..533] of)
                (NP (NN:[534..537] MPH)))
              (PP (IN:[538..540] on)
                (NP
                  (NP-1 (NN:[541..547] CYP450) (NNS:[548..556] isozymes))
                  (ADJP (JJ:[557..563] likely)
                    (S
                      (NP-SBJ-1 (-NONE-:[563..563] *))
                      (VP (TO:[564..566] to)
                        (VP (VB:[567..569] be)
                          (ADJP-PRD (JJ:[570..579] important)
                            (PP (IN:[580..582] in)
                              (NP
                                (NP (DT:[583..586] the)
                                    (NN:[588..599] interaction))
                                (PP (IN:[600..607] between)
                                  (NP
                                    (NP (NN:[608..611] MPH))
                                    (CC:[612..615] and)
                                    (NP (NN:[616..626] imipramine))))))))))))))))))
    (.:[626..627] .)))

;sentence 6 Span:628..730
;Single high doses of MPH (25, 50 and 100  mg/kg, i.p.) were administered to
;simulate the abuse of MPH.
;[649..652]:substance:"MPH"
;[654..656]:quantitative-value:"25"
;[658..660]:quantitative-value:"50"
;[665..668]:quantitative-value:"100"
;[670..675]:quantitative-units:"mg/kg"
;[726..729]:substance:"MPH"
(SENT
  (S
    (NP-SBJ-2
      (NP
        (NP (JJ:[628..634] Single) (JJ:[635..639] high) (NNS:[640..645] doses))
        (PP (IN:[646..648] of)
          (NP (NN:[649..652] MPH))))
      (PRN (-LRB-:[653..654] -LRB-)
        (FRAG
          (NP
            (NP
              (NP (CD:[654..656] 25)
                (NML-1 (-NONE-:[656..656] *P*))
                (PP-3 (-NONE-:[656..656] *RNR*)))
              (,:[656..657] ,)
              (NP (CD:[658..660] 50)
                (NML-1 (-NONE-:[660..660] *P*))
                (PP-3 (-NONE-:[660..660] *RNR*)))
              (CC:[661..664] and)
              (NP (CD:[665..668] 100)
                (NML-1 (NN:[670..672] mg))
                (PP-3 (-NONE-:[672..672] *RNR*))))
            (PP-3 (SYM:[672..673] /)
              (NP (NN:[673..675] kg))))
          (,:[675..676] ,)
          (ADVP (RB:[677..681] i.p.)))
        (-RRB-:[681..682] -RRB-)))
    (VP (VBD:[683..687] were)
      (VP (VBN:[688..700] administered)
        (NP-2 (-NONE-:[700..700] *))
        (S-PRP
          (NP-SBJ (-NONE-:[700..700] *))
          (VP (TO:[701..703] to)
            (VP (VB:[704..712] simulate)
              (NP
                (NP (DT:[713..716] the) (NN:[717..722] abuse))
                (PP (IN:[723..725] of)
                  (NP (NN:[726..729] MPH)))))))))
    (.:[729..730] .)))

;sentence 7 Span:731..809
;Under these  conditions, MPH decreased total hepatic CYP450 to 50% of
;control.
;[756..759]:substance:"MPH"
;[784..790]:cyp450:"CYP450"
;[794..797]:quantitative-value:"50%"
(SENT
  (S
    (PP (IN:[731..736] Under)
      (NP (DT:[737..742] these) (NNS:[744..754] conditions)))
    (,:[754..755] ,)
    (NP-SBJ (NN:[756..759] MPH))
    (VP (VBD:[760..769] decreased)
      (NP (JJ:[770..775] total) (JJ:[776..783] hepatic) (NN:[784..790] CYP450))
      (PP-EXT (TO:[791..793] to)
        (NP
          (NP (CD:[794..796] 50) (NN:[796..797] %))
          (PP (IN:[798..800] of)
            (NP (NN:[801..808] control))))))
    (.:[808..809] .)))

;sentence 8 Span:810..944
;Additionally,  MPH inhibited the catalytic activity of CYP1A and CYP2E1 by
;50%, and decreased  the polypeptide levels of CYP3A by 30%.
;[825..828]:substance:"MPH"
;[865..870]:cyp450:"CYP1A"
;[875..881]:cyp450:"CYP2E1"
;[885..888]:quantitative-value:"50%"
;[931..936]:cyp450:"CYP3A"
;[940..943]:quantitative-value:"30%"
(SENT
  (S
    (ADVP (RB:[810..822] Additionally))
    (,:[822..823] ,)
    (NP-SBJ (NN:[825..828] MPH))
    (VP
      (VP (VBD:[829..838] inhibited)
        (NP
          (NP (DT:[839..842] the) (JJ:[843..852] catalytic)
              (NN:[853..861] activity))
          (PP (IN:[862..864] of)
            (NP (NN:[865..870] CYP1A) (CC:[871..874] and) (NN:[875..881] CYP2E1))))
        (PP-EXT (IN:[882..884] by)
          (NP (CD:[885..887] 50) (NN:[887..888] %))))
      (,:[888..889] ,) (CC:[890..893] and)
      (VP (VBD:[894..903] decreased)
        (NP
          (NP (DT:[905..908] the) (NN:[909..920] polypeptide)
              (NNS:[921..927] levels))
          (PP (IN:[928..930] of)
            (NP (NN:[931..936] CYP3A))))
        (PP-EXT (IN:[937..939] by)
          (NP (CD:[940..942] 30) (NN:[942..943] %)))))
    (.:[943..944] .)))

;sentence 9 Span:945..1107
;In a second study designed to simulate  more closely therapeutic use, MPH was
;administered orally for two weeks at  10-fold lower doses (2.5, 5 and 10
;mg/kg/day).
;[1015..1018]:substance:"MPH"
;[1047..1050]:quantitative-value:"two"
;[1051..1056]:quantitative-units:"weeks"
;[1061..1074]:quantitative-value:"10-fold lower"
;[1082..1085]:quantitative-value:"2.5"
;[1087..1088]:quantitative-value:"5"
;[1093..1095]:quantitative-value:"10"
;[1096..1105]:quantitative-units:"mg/kg/day"
(SENT
  (S
    (PP (IN:[945..947] In)
      (NP
        (NP (DT:[948..949] a) (JJ:[950..956] second) (NN:[957..962] study))
        (VP (VBN:[963..971] designed)
          (S
            (NP-SBJ (-NONE-:[971..971] *))
            (VP (TO:[972..974] to)
              (VP (VB:[975..983] simulate)
                (NP
                  (ADJP
                    (ADVP (RBR:[985..989] more) (RB:[990..997] closely))
                    (JJ:[998..1009] therapeutic))
                  (NN:[1010..1013] use))))))))
    (,:[1013..1014] ,)
    (NP-SBJ-3 (NN:[1015..1018] MPH))
    (VP (VBD:[1019..1022] was)
      (VP (VBN:[1023..1035] administered)
        (NP-3 (-NONE-:[1035..1035] *))
        (ADVP (RB:[1036..1042] orally))
        (PP-TMP (IN:[1043..1046] for)
          (NP (CD:[1047..1050] two) (NNS:[1051..1056] weeks)))
        (PP (IN:[1057..1059] at)
          (NP
            (NP
              (ADJP
                (ADJP-EXT (CD:[1061..1063] 10) (HYPH:[1063..1064] -)
                          (RB:[1064..1068] fold))
                (JJR:[1069..1074] lower))
              (NNS:[1075..1080] doses))
            (PP (-LRB-:[1081..1082] -LRB-)
              (NP
                (NP
                  (NP (CD:[1082..1085] 2.5)
                    (NML-1 (-NONE-:[1085..1085] *P*)))
                  (,:[1085..1086] ,)
                  (NP (CD:[1087..1088] 5)
                    (NML-1 (-NONE-:[1088..1088] *P*)))
                  (CC:[1089..1092] and)
                  (NP (CD:[1093..1095] 10)
                    (NML-1 (NN:[1096..1098] mg))))
                (PP (SYM:[1098..1099] /)
                  (NP (NN:[1099..1101] kg)))
                (PP (SYM:[1101..1102] /)
                  (NP (NN:[1102..1105] day))))
              (-RRB-:[1105..1106] -RRB-))))))
    (.:[1106..1107] .)))

;sentence 10 Span:1108..1271
;MPH decreased total hepatic  CYP450 at both 5 and 10 mg/ kg/day (0.96 +/-
;0.01 and 0.96 +/- 0.06 nmol/mg  versus 1.34 +/- 0.01 nmol/mg for saline
;control, P<0.05).
;[1108..1111]:substance:"MPH"
;[1137..1143]:cyp450:"CYP450"
;[1152..1153]:quantitative-value:"5"
;[1158..1160]:quantitative-value:"10"
;[1161..1171]:quantitative-units:"mg/ kg/day"
;[1173..1186]:quantitative-value:"0.96 +/- 0.01"
;[1191..1204]:quantitative-value:"0.96 +/- 0.06"
;[1205..1212]:quantitative-units:"nmol/mg"
;[1221..1234]:quantitative-value:"1.34 +/- 0.01"
;[1235..1242]:quantitative-units:"nmol/mg"
;[1247..1253]:substance:"saline"
;[1254..1261]:substance:"control"
(SENT
  (S
    (NP-SBJ (NN:[1108..1111] MPH))
    (VP (VBD:[1112..1121] decreased)
      (NP (JJ:[1122..1127] total) (JJ:[1128..1135] hepatic)
          (NN:[1137..1143] CYP450))
      (PP (IN:[1144..1146] at)
        (NP
          (NP (CC:[1147..1151] both)
            (NML (CD:[1152..1153] 5)
              (NML-2 (-NONE-:[1153..1153] *P*)))
            (CC:[1154..1157] and)
            (NML (CD:[1158..1160] 10)
              (NML-2 (NN:[1161..1163] mg))))
          (PP (SYM:[1163..1164] /)
            (NP (NN:[1165..1167] kg)))
          (PP (SYM:[1167..1168] /)
            (NP (NN:[1168..1171] day)))))
      (PP (-LRB-:[1172..1173] -LRB-)
        (FRAG
          (NP
            (NP
              (NP
                (NP
                  (QP (CD:[1173..1177] 0.96) (SYM:[1178..1181] +/-)
                      (CD:[1182..1186] 0.01))
                  (NML-1 (-NONE-:[1186..1186] *P*)))
                (CC:[1187..1190] and)
                (NP
                  (QP (CD:[1191..1195] 0.96) (SYM:[1196..1199] +/-)
                      (CD:[1200..1204] 0.06))
                  (NML-1 (NN:[1205..1209] nmol))))
              (PP (SYM:[1209..1210] /)
                (NP (NN:[1210..1212] mg))))
            (PP (IN:[1214..1220] versus)
              (NP
                (NP
                  (NP
                    (QP (CD:[1221..1225] 1.34) (SYM:[1226..1229] +/-)
                        (CD:[1230..1234] 0.01))
                    (NN:[1235..1239] nmol))
                  (PP (SYM:[1239..1240] /)
                    (NP (NN:[1240..1242] mg))))
                (PP (IN:[1243..1246] for)
                  (NP (NN:[1247..1253] saline) (NN:[1254..1261] control))))))
          (,:[1261..1262] ,)
          (S
            (NP-SBJ (NN:[1263..1264] P))
            (VP (SYM:[1264..1265] <)
              (NP (CD:[1265..1269] 0.05)))))
        (-RRB-:[1269..1270] -RRB-)))
    (.:[1270..1271] .)))

;sentence 11 Span:1272..1455
;The catalytic activity  and protein levels of CYP1A were diminished by up to
;50% of control, while  catalytic activity and polypeptide levels for CYP2E1
;and CYP3A remained  unchanged.
;[1300..1307]:substance:"protein"
;[1318..1323]:cyp450:"CYP1A"
;[1349..1352]:quantitative-value:"50%"
;[1418..1424]:cyp450:"CYP2E1"
;[1429..1434]:cyp450:"CYP3A"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1272..1275] The)
        (NML
          (NML (JJ:[1276..1285] catalytic) (NN:[1286..1294] activity))
          (CC:[1296..1299] and)
          (NML (NN:[1300..1307] protein) (NNS:[1308..1314] levels))))
      (PP (IN:[1315..1317] of)
        (NP (NN:[1318..1323] CYP1A))))
    (VP (VBD:[1324..1328] were)
      (VP (VBN:[1329..1339] diminished)
        (NP-1 (-NONE-:[1339..1339] *))
        (PP (IN:[1340..1342] by)
          (NP-EXT
            (NP
              (QP (IN:[1343..1345] up) (TO:[1346..1348] to) (CD:[1349..1351] 50))
              (NN:[1351..1352] %))
            (PP (IN:[1353..1355] of)
              (NP (NN:[1356..1363] control)))))
        (,:[1363..1364] ,)
        (SBAR-ADV (IN:[1365..1370] while)
          (S
            (NP-SBJ
              (NP
                (NP (JJ:[1372..1381] catalytic) (NN:[1382..1390] activity))
                (CC:[1391..1394] and)
                (NP (NN:[1395..1406] polypeptide) (NNS:[1407..1413] levels)))
              (PP (IN:[1414..1417] for)
                (NP (NN:[1418..1424] CYP2E1) (CC:[1425..1428] and)
                    (NN:[1429..1434] CYP3A))))
            (VP (VBD:[1435..1443] remained)
              (ADJP-PRD (JJ:[1445..1454] unchanged)))))))
    (.:[1454..1455] .)))

;sentence 12 Span:1456..1563
;These results indicate that MPH inhibits the CYP450 system following  both
;abuse and therapeutic scenarios.
;[1484..1487]:substance:"MPH"
;[1501..1507]:cyp450:"CYP450"
(SENT
  (S
    (NP-SBJ (DT:[1456..1461] These) (NNS:[1462..1469] results))
    (VP (VBP:[1470..1478] indicate)
      (SBAR (IN:[1479..1483] that)
        (S
          (NP-SBJ (NN:[1484..1487] MPH))
          (VP (VBZ:[1488..1496] inhibits)
            (NP (DT:[1497..1500] the) (NN:[1501..1507] CYP450)
                (NN:[1508..1514] system))
            (S-MNR
              (NP-SBJ (-NONE-:[1514..1514] *))
              (VP (VBG:[1515..1524] following)
                (NP (CC:[1526..1530] both)
                  (NML
                    (NML (NN:[1531..1536] abuse)
                      (NML-1 (-NONE-:[1536..1536] *P*)))
                    (CC:[1537..1540] and)
                    (NML (JJ:[1541..1552] therapeutic)
                      (NML-1 (NNS:[1553..1562] scenarios)))))))))))
    (.:[1562..1563] .)))

;sentence 13 Span:1564..1669
;However, this effect was dependent on both  the isoform of CYP450 and the
;duration of MPH administration.
;[1612..1619]:cyp450:"isoform"
;[1623..1629]:cyp450:"CYP450"
;[1650..1653]:substance:"MPH"
(SENT
  (S
    (ADVP (RB:[1564..1571] However))
    (,:[1571..1572] ,)
    (NP-SBJ (DT:[1573..1577] this) (NN:[1578..1584] effect))
    (VP (VBD:[1585..1588] was)
      (ADJP-PRD (JJ:[1589..1598] dependent)
        (PP (IN:[1599..1601] on)
          (NP (CC:[1602..1606] both)
            (NP
              (NP (DT:[1608..1611] the) (NN:[1612..1619] isoform))
              (PP (IN:[1620..1622] of)
                (NP (NN:[1623..1629] CYP450))))
            (CC:[1630..1633] and)
            (NP
              (NP (DT:[1634..1637] the) (NN:[1638..1646] duration))
              (PP (IN:[1647..1649] of)
                (NP (NN:[1650..1653] MPH) (NN:[1654..1668] administration))))))))
    (.:[1668..1669] .)))

;section 14 Span:1673..1718
;PMID: 12141399 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1673..1677] PMID) (::[1677..1678] :) (CD:[1679..1687] 12141399)
        (NN:[1688..1689] -LSB-) (NNP:[1689..1695] PubMed) (::[1696..1697] -)
        (NN:[1698..1705] indexed) (IN:[1706..1709] for)
        (NNP:[1710..1718] MEDLINE-RSB-)))
